Clinical assessments
inflammation, tumor, Cancer
TUMOR, INFLAMMATION, CARDIOPULMONARY, SECONDARY, DILATION, CANCER
All patients were assessed at baseline and 3 and 6 months (study visit 2 and 3) after randomization. The CRBP-TS application measured and evaluated the daily activity of patients in the IG and CG. All study subjects underwent clinical examinations according to standard operating procedures; this included medical history, anthropometry (BIACORPUS RX 4004 M, MEDI CAL HealthCare GmbH, Germany), flow-mediated dilation, blood analysis (clinical chemistry; tumor and inflammation marker panel) cardiopulmonary exercise testing, and completing the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QoLQ-C30). Subjects also underwent cardiopulmonary exercise testing to determine primary and secondary end points (custo, BT300 electrocardiogram, custo GmbH, Germany; PhysioFlow impedance cardiography, Manatec Biomedical, France; Dynostics ergo-spirometry, Sicada GmbH, Germany) on an electronically braked semi-recumbent ergometer. The initial load was 30 Watts with 10 Watts/min increments until subjective or objective exhaustion or the occurrence of termination criteria [Staff members conducting the evaluations were not blinded to treatment groups. Cardiopulmonary exercise capacity was tested according to current recommendations [